louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02843360: National Health Interview Survey in Taiwan
Official title: National Health Interview Survey in Taiwan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Public Health
Keywords: public health
Lead sponsor: National Health Research Institutes, Taiwan
Sponsor class: OTHER
First posted: 2016-07-25
Enrollment: 23296
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: All the community dwelling people were eligible for the survey.

Brief summary: The major elements of the survey were sampling, questionnaire design, field survey and database construction. This survey incorporated the multistage stratified sampling scheme. Questionnaires include health status, utilization of health care, health behaviors, quality of life, and social economic status.

Detailed description: This survey took a representative sample from each county and municipality in Taiwan using a stratified multi-stage systematic sampling procedure. Within each county/municipality (stratum), samples were selected with probability proportional to population size. Questionnaire design was based on the needs of the Department of Health and Welfare and the public health professionals. Due to different age has different health problems, the questionnaires were divided into 3 parts: under 12, 23-64, and 65+ years. The response rate was 75% in 2013.

Eligibility criteria: Inclusion Criteria:

* All the selected samples were to be interviewed.

Exclusion Criteria:

* severely ill or too frail to answer;
* having cognitive problems;
* having hearing or speaking problems; or
* dementia.

Primary outcomes:
measure: Health Status of the General Population
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06111560: Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell Carcinoma
Official title: Exploring the Influence of Clinical Factors on the Prognosis of Papillary Renal Cell
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carcinoma, Renal Cell
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-11-01
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All the enrolled patients were Asian(we are a affiliated hospital of a university based in Mailand china ).

Brief summary: Patients with renal cell carcinoma who were admitted to the First Affiliated Hospital of Sun Yat-sen University from February 1, 2021, to February 1, 2022, and met the following inclusion and exclusion criteria were collected. Clinical factors influencing the prognosis of enrolled patients were retrospectively analyzed, and a predictive system was established based on this.

(Inclusion criteria: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center.

Exclusion criteria:a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up.)


Eligibility criteria: Inclusion Criteria:

a: pathology of the surgical specimen confirmed the diagnosis of pRCC,b: age 18 years or older, c: localized RCC underwent radical nephrectomy or partial nephrectomy in our center

Exclusion Criteria:

a: lack of original CT images, b: patients with malignant tumors of other systems, c: patients who lost follow-up

Primary outcomes:
measure: Tumor progression
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: First affiliated hospital, Sun Yat-sen univeristy
name: Wenhui Su, Bachelor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00002360: A Study Comparing Two Forms of Didanosine in HIV-infected Patients
Official title: Pivotal Bioequivalence Study of Videx Chewable/Dispersible Buffered Tablets and an Encapsulated Enteric Coated Bead Formulation of Didanosine in HIV-Infected Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: HIV Infections
Keywords: Didanosine
Tablets
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Therapeutic Equivalency
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if the coated-capsule form of didanosine (ddI) is as safe and absorbed by the body as well as the chewable-tablet form of ddI.

Didanosine (ddI) is an anti-HIV drug. The effectiveness of ddI can be lowered by acid in the stomach. To prevent this, patients take antacids with ddI. The coated-capsule form of ddI may replace the need for antacids.

Detailed description: Didanosine, a purine nucleoside analogue, is indicated for the treatment of HIV infection when antiretroviral therapy is warranted. Didanosine is administered orally with antacids to protect it against acid-induced hydrolysis in the stomach. To eliminate the need for using buffers in the ddI formulations, an enteric-coated bead formulation of ddI is being developed.

Patients are randomized to 1 of 2 groups to receive treatment on 2 separate occasions at least 72 hours apart. Group 1 receives the reference formulation of ddI. Group 2 receives the test formulation of ddI. Clinical evaluations, including clinical laboratory tests, are performed periodically during the study and at discharge. Serial blood samples are collected at specific time points over the 12 hours following dosing, and are used for the pharmacokinetic variables CMAX and AUC(INF). Factors used in analysis are sequence, subject within sequence, period, and formulation. Safety is assessed by monitoring adverse effects, vital signs, ECG recordings, and clinical laboratory tests throughout the study.

Eligibility criteria: Inclusion Criteria

Patients must have:

* HIV infection.
* CD4 cell counts of at least 200 cells/mm3.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Any evidence of organ dysfunction.
* Any clinically significant deviations from specified baseline requirements for physical examinations, laboratory tests, or 12-lead electrocardiogram.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
name: Catherine A. Knupp
role: STUDY_DIRECTOR
References:
Clinical trial NCT00502060: Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer
Official title: A Phase I Open-Label Study to Assess the Safety, Tolerability and PK of Ascending Multiple Oral Doses of AZD2171 When co-Administered With Fixed Multiple Oral Doses of ZD1839 (250mg or 500mg Once Daily) in Patients With Advanced Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Tumor
Keywords: Phase I
AZD2171
ZD1839
solid tumor
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2007-07-17
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase I AZD2171 in combination with ZD1839 study recruiting patients with advanced cancer


Eligibility criteria: Inclusion Criteria:

* tumor progressed on standard therapy or ineligible for standard therapy
* life expectancy of 12 weeks or more
* WHO performance status 0-2

Exclusion Criteria:

* History of active interstitial lung disease

Primary outcomes:
measure: primary objective is to determine the safety and tolerability of multiple oral doses fo AZD2171 when co-administered with fixed daily oral doses of ZD1839
Secondary outcomes:
measure: to explore the PK of AZD2171 when given alone for 7 days and in combination with ZD1839 for 14 days
Other outcomes:
Locations:
city: Amsterdam
country: Netherlands
facility: Research Site
city: Nijmegen
country: Netherlands
facility: Research Site
city: Utrecht
country: Netherlands
facility: Research Site
Study officials:
affiliation: AstraZeneca
name: Nick Botwood, BSc, MBBS, MRCP, MFPM
role: STUDY_DIRECTOR
affiliation: Vrije Universiteit Medical Centre
name: G Giaccone, Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02455960: Protective Effects of Oral L-Arginine CI-AKI
Official title: Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Contrast Induced AKI
Lead sponsor: Phramongkutklao College of Medicine and Hospital
Sponsor class: OTHER
First posted: 2015-05-28
Enrollment: 112
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This trial was performed to examine the efficacy of oral L-arginine for preventing CI-AKI in chronic kidney disease (CKD) patients.

Detailed description: Contrast-induced acute kidney injury (CI-AKI) is a common complication in hospitalized patients. Nitric oxide-signal transduction plays an important role in prevention of CI-AKI. L-Arginine is an amino acid involved in ammonia detoxification, and is well known as a precursor to nitric oxide, a key component of endothelial-derived relaxing factor.

This is a prospective randomized, double blind, placebo controlled trial among CKD stage 3-4 patients undergoing computer tomography. Eligible patients were randomly assigned to two groups: (1) arginine 3 g/day or 6 capsules per day, and (2) placebo 6 capsules per day for 3 days before contrast media injection. Serum cystatin C, serum creatinine and estimated GFR was measured at baseline and 48 hours after procedure.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Stable CKD stage 3-4 patients
* Patients undergoing elective contrast media injection

Exclusion Criteria:

* History of arginine allergy
* Acute kidney injury diagnosed within 4 weeks
* Active infection/sepsis
* Severe liver disease

Primary outcomes:
measure: Incidence of Contrast-induced acute kidney injury (CI-AKI)
timeFrame: 48 hours
Secondary outcomes:
measure: Number of Adverse effects
timeFrame: 48 hours
Other outcomes:
Locations:
city: Rachatevee
country: Thailand
facility: Division of Nephrology, Phramongkutklao Hospital
state: Bangkok
Study officials:
References:
Clinical trial NCT03230760: Acupuncture for Breast Engorgement During Lactation
Official title: Acupuncture for Breast Engorgement During Lactation: a Pilot Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Engorgement
Keywords: acupuncture
breast engorgement
lactation
Lead sponsor: Taichung Veterans General Hospital
Sponsor class: OTHER
First posted: 2017-07-26
Enrollment: 60
Sex: FEMALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Breast engorgement which may manifest swell, throb, and cause mild to extreme pain is the common difficulty for breast feeding woman. It occurs in the mammary glands due to expansion and pressure exerted by the synthesis and storage of breast milk and it usually happens when the breasts switch from colostrums to mature milk. However, engorgement can also happen if lactating women miss several nursing and not enough milk is expressed from the breasts. It can be exacerbated by insufficient breastfeeding and/or blocked milk ducts. Engorgement may lead to mastitis and untreated engorgement puts pressure on the milk ducts, often causing a plugged duct.

According the meridian theory, the investigators propose the acupuncture treatment for patients of breast engorgement.

The investigators will include 60 patients and measure the acupuncture effect. The inclusion criteria are women with breast engorgement and 20 years old or older. Exclusion standards are patients with: 1. diabetes mellitus 2. Psychological disease or mental illness 3. Fever \> 38 degrees Celsius 4. Mastitis 5.analgetics or anti - inflammatory agents used 6. ultrasound therapy applied


Eligibility criteria: Inclusion Criteria:

* women with breast engorgement and 20 years old or older

Exclusion Criteria:

* patients with:

  1. diabetes mellitus
  2. psychological disease or mental illness
  3. Fever \> 38 degrees Celsius
  4. Mastitis
  5. analgesics or anti - inflammatory agents used
  6. ultrasound therapy applied

Primary outcomes:
measure: breast engorgement
timeFrame: 3 days
Secondary outcomes:
measure: mastitis
timeFrame: 3 days
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Taichung
country: Taiwan
facility: TCM
Study officials:
affiliation: Traditional Chinese Medicine department
name: PeiJung Chiang
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mangesi L, Zakarija-Grkovic I. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2016 Jun 28;2016(6):CD006946. doi: 10.1002/14651858.CD006946.pub3.
citation: Crepinsek MA, Taylor EA, Michener K, Stewart F. Interventions for preventing mastitis after childbirth. Cochrane Database Syst Rev. 2020 Sep 29;9(9):CD007239. doi: 10.1002/14651858.CD007239.pub4.
citation: Zakarija-Grkovic I, Stewart F. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2020 Sep 18;9(9):CD006946. doi: 10.1002/14651858.CD006946.pub4.
Clinical trial NCT02845960: The Influence of Rapid Recovery on Sleep Quality Following Total Knee Replacement Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Arthroplasty, Replacement, Knee
Recovery of Function
Arthritis, Rheumatoid
Lead sponsor: Southwest Hospital, China
Sponsor class: OTHER
First posted: 2016-07-27
Enrollment: 170
Sex: ALL
Minimum age (years): 20
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Chinese

Brief summary: The purpose of this study is to evaluate the influence of rapid recovery on sleep quality following total knee replacement surgery.


Eligibility criteria: Inclusion Criteria:

1. Primary unilateral total knee artropasty;
2. Patients with Knee osteoartritis or Rheumatoid arthritis;
3. Able and willing to provide signed informed consent.

Exclusion Criteria:

1. Simultaneously bilateral total knee artropasty or revision case;
2. Surgical History of the knee joint;
3. Knee joint cavity paracentesis in recent 3 months;
4. Stiffness with knee;
5. Blood coagulation disorders;
6. History of deep venous thrombosis;
7. Concomitant medical problems such as uncontrolled hypertention, severe cardiovascular disorder, chronic obstructive pulmonary disease, liver or renal failure
8. allergic to NSAIDs, opioid analgesics, zolpidem
9. sleep apnea, Parkinson disease, dementia, depression
10. use of sedatives or hypnotics
11. inability to comply with polysomnographic measurement

Primary outcomes:
measure: WOMAC score
timeFrame: 1 mounth
measure: GAD-7
timeFrame: 1 mounth
measure: PSQI index
timeFrame: 1 mounth
measure: Insomnia severity index
timeFrame: 1 mounth
measure: polysomnographic measurement
timeFrame: 1 mounth
measure: VAS
timeFrame: 1 mounth
measure: Range of motion
timeFrame: 1 mounth
Secondary outcomes:
Other outcomes:
Locations:
city: Chongqing
country: China
facility: Southwest Hospital
state: Chongqing
Study officials:
References:
Clinical trial NCT03783260: Investigation of Microbiome-Derived Metabolite Production in Response to a Mediterranean Diet
Official title: Investigation of Microbiome-Derived Metabolite Production in Response to a Mediterranean Diet
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Habits
Keywords: Gut Microbiome
Metabolites
Endocannabinoid
Mediterranean diet
Lead sponsor: Laval University
Sponsor class: OTHER
First posted: 2018-12-21
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This project proposes to characterise the microbiome-derived metabolites produced upon ingestion of bioactive precursor-rich meals by healthy volunteers in order to investigate the relationship between gut microbiome composition and the nature of dietary metabolites production.

Detailed description: There is a large inter-individual variability in gut microbiome-derived metabolites production upon ingestion of similar meals. Since many of these microbiome-derived metabolites have enteric and systemic biological effects, these variabilities could in part account for the different responses to meals and diets.

This project thus aims to improve the understanding the relationship between gut microbiome composition and the nature of dietary metabolites produced from similar bioactive precursor-rich meals.

The investigators therefore propose to characterise the circulating microbiome-derived metabolite profiles in healthy individuals fed the same 2-day precursor-rich Mediterranean diet prior to and after a 2-week of habitual Canadian diet feeding.

Eligibility criteria: Inclusion Criteria:

* Men and women aged between 18 and 35 years
* Body mass index between 18.5 and 30 kg/m2
* General good health
* Computer and Internet access
* Basic understanding of written French

Exclusion Criteria:

* Intestinal pathologies including inflammatory bowel disease and gastrointestinal cancers
* Pregnant and/or breast-feeding women
* Alcohol consumption greater than 15 portions for men and 10 for women weekly
* Active tobacco usage
* Consumption of dietary supplements (e.g. multivitamins, omega-3, probiotics)
* Completion of a course of antibiotics in the past 3 months
* Regular use of anti-inflammatory drugs, or use in the past 3 months
* Important weight change (+/- 5 kg) in the past 6 months
* Allergies or food intolerances to ingredients present in trial diets

Primary outcomes:
measure: Microbiome-derived metabolite profiling
timeFrame: 19 days
measure: Gut microbiome characterisation
timeFrame: 19 days
Secondary outcomes:
measure: Endocannabinoid interaction with interindividual microbiome composition
timeFrame: 19 days
Other outcomes:
Locations:
city: Québec
country: Canada
facility: Institut sur la nutrition et les aliments fonctionnels - INAF
state: Quebec
Study officials:
References:
Clinical trial NCT01623960: Quality of Life in Adult Patients With Severe Haemophilia in Turkey
Official title: A Nationwide Multicenter Study on the Quality of Life in Adult Patients With Severe Haemophilia in Turkey
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Haemophilia
Keywords: severe haemophilia
quality of life
Lead sponsor: Turkish Society of Hematology
Sponsor class: OTHER
First posted: 2012-06-20
Enrollment: 500
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult male patient with severe haemophilia followed at 10 different haemophilia centers in Turkey

Brief summary: The primary aim of this study is to evaluate the overall quality of life in adult patients with severe haemophilia (an inherited bleeding disorder affecting mainly men) in Turkey and to assess the impact of certain disease and drug related factors (treatment modality, presence of viral disease, inhibitor, etc.) on the quality of life.

Detailed description: Haemophilia is an inherited bleeding disorder affecting one in 10000 male births worldwide. People with severe haemophilia usually suffer from recurrent life threatening bleeds (e.g. into the brain, digestive system or abdomen) and/or disabling degenerative disease of weight bearing joints (e.g. knees, elbows and ankles)resulting from haemorrhage into the joints. Daily activities of people with haemophilia has been shown to be dramatically hampered by the resultant joint damage. Evaluation of quality of life issues in people with severe haemophilia would help to create awareness of their problems and limitations. This would also set up the scene for developing policies to improve the treatment options/facilities and social life of the patients. Current study aims to assess the quality of life of adult patients with severe haemophilia in a developing country (Turkey) by using a validated Quality of Life Questionnaire (Turkish version of Haem-A-QoL).

Eligibility criteria: Inclusion Criteria:

* age equal or greater than 18 years
* male gender
* factor VIII or IX level equal or below 1%
* patients that are willing to participate and have given a written consent

Exclusion Criteria:

* age less than 18 years
* females
* factor levels above 1%

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: